Key result
The novel PAR1 antagonist SCH 530348 demonstrated potent antiplatelet activity without increasing bleeding risk (2.8% vs 3.3% for placebo) when added to standard therapy in a phase 2 trial.
Why the study?
Does the PAR1 antagonist SCH 530348 reduce ischemic events without increasing bleeding risk in patients with atherothrombotic disease?
Population
Patients with atherothrombotic disease and preclinical models of thrombosis
Comparison
PAR1 antagonist SCH 530348 added to standard… vs Standard antiplatelet therapy alone
Design
Review
Authors
Loading...
Phase 2 data on SCH 530348 justify phase 3 trials; leaves open net clinical benefit in atherothrombotic disease.
Does the PAR1 antagonist SCH 530348 reduce ischemic events without increasing bleeding risk in patients with atherothrombotic disease?
PAR1 antagonism with SCH 530348 is a novel antiplatelet strategy that shows promise in early studies for reducing atherothrombotic events without increasing bleeding risk.
Chintala et al. (2008) conducted a review in Atherothrombotic disease. SCH 530348 vs. Placebo / Standard of care was evaluated. The novel PAR1 antagonist SCH 530348 demonstrated potent antiplatelet activity without increasing bleeding risk (2.8% vs 3.3% for placebo) when added to standard therapy in a phase 2 trial.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: